Intensive Risk-Adjusted Follow-up With the CEA, TPA, CA19.9, and CA72.4 Tumor Marker Panel and Abdominal Ultrasonography to Diagnose Operable Colorectal Cancer Recurrences

Nicolini, Andrea; Ferrari, Paola; Duffy, Michael J.; Antonelli, Alessandro; Rossi, G; Metelli, Maria Rita; Fulceri, Federica; Anselmi, L; Conte, Massimo; Berti, Piero; Miccoli, Paolo

doi:10.1001/archsurg.2010.251

Cited by 44 publications

(26 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As regards CA724, recent studies have mainly focused on the sensitivity and specificity of its diagnostic and early detection value for recurrences. The combinations of CA724 with other STMs were considered to be satisfactory (10,13,(15)(16)(17). In our study, we focused on the differences in the CA724 levels among patients with different disease stages.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma

Zhu

Chen

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of this study was to investigate tumor biomarker carbohydrate antigen 724 (CA724) in the serum of patients with carcinomas of the colon and rectum at various clinical stages. Serum was collected from 51 patients with colon carcinoma (CC) and 49 patients with rectal carcinoma (RC). CA724 levels were then measured in the different groups according to site, TNM classification, gender, age and metastastic status of the patients. The statistical significance of the differences between the groups was calculated by non-parametric statistics (Mann-Whitney and Kruskall-Wallis tests). We observed a close association between the serum CA724 levels and tumor migration in colorectal carcinoma (CRC) and opposite variation tendencies of CA724 in the evolution of CC and RC. In conclusion, we identified a close association between the serum levels of CA724 and tumor migration in CRC. The opposite variation tendencies of CA724 in the different evolution groups of CC and RC may reflect the differences between these two types of cancer. The evaluation of serum CA724 may be of monitoring and and predictive value and may also assist in the development of treatment strategies for CRC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It was demonstrated that the combined use of carcionembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 was effective in the screening and diagnosis of CRC (11). CA724 was previously identified as a type of STM specific for gastric cancer (12) and the correlation between CA724 and CRC has been attracting increasing attention (13).…”

Section: Introductionmentioning

confidence: 99%

Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma

Zhu

Chen

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Although CEA is the elected serum tumor marker for colorectal cancer surveillance, Ca19-9 has also proven to be of value in these patients, although its routine use is discouraged by the European Group on Tumor Markers (EGTM, 2007). However, there is data that Ca 19-9 increase during follow up is as indicative for recurrence as CEAq like in the study of Kawamura et al (2010), although controversial data also exist (Nicolini et al, 2010). The reported positive predictive value of Ca 19-9 for recurrence in a study from Park et al (2009) reaches 59% with peritoneal metastases being most frequently associated with elevated marker.…”

Section: Introductionmentioning

confidence: 92%

Positive predictive value of CEA and Ca19-9 as tumor markers for recurrent colorectal cancer in cases where conventional work-up fail to localize disease.

Bocheva¹,

Bochev²

2015

EMHPJ

View full text Add to dashboard Cite

show abstract

“…Most of the studies report increased levels of TPA and TPS in the metastatic stage of CRC. Some studies suggested that the combination of TPA and CEA has greater sensitivity and can identify recurrence in CRC patients [9–12]. …”

Section: Currently Available Blood-based Testsmentioning

confidence: 99%

Colorectal Cancer Blood-Based Biomarkers

Hauptman

Glavač

2017

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Mortality and morbidity associated with colorectal cancer (CRC) are increasing globally, partly due to lack of early detection of the disease. The screening is usually performed with colonoscopy, which is invasive and unpleasant, discouraging participation in the screening. As a source of noninvasive and easily accessible biomarkers, liquid biopsies are emerging. Blood-based biomarkers have the potential as diagnostic and prognostic tool in CRC. Early stage detection of CRC with high sensitivity and specificity would likely lead to higher participation in the screening test. It would also improve the prognosis of the disease and improve the recurrence risk. In this review, we summarize the potential biomarkers for early detection and monitoring of CRC.

show abstract

Intensive Risk-Adjusted Follow-up With the CEA, TPA, CA19.9, and CA72.4 Tumor Marker Panel and Abdominal Ultrasonography to Diagnose Operable Colorectal Cancer Recurrences

Abstract: Long-term intensive risk-adjusted monitoring using the CEA, TPA, CA19.9, and CA72.4 TM panel and abdominal ultrasonography allows early detection of most recurrences. Patients can then undergo radical metastasectomy, with potentially improved overall survival.

Cited by 44 publications

References 46 publications

Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma

Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma

Positive predictive value of CEA and Ca19-9 as tumor markers for recurrent colorectal cancer in cases where conventional work-up fail to localize disease.

Colorectal Cancer Blood-Based Biomarkers

Contact Info

Product

Resources

About